preoperative administration of interleukin-2 (IL-2)	immunomonitoring without immunomodulation	Tumour-specific survival after 5 years	1639	1767	Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04)
preoperative administration of interleukin-2 (IL-2)	immunomonitoring without immunomodulation	Tumour-specific survival after 1 year	1639	1768	Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04).
preoperative administration of interleukin-2 (IL-2)	immunomonitoring without immunomodulation	Tumour-specific survival after 1 year	1639	1730	Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year
IL-2	Control	IL-2-related toxicity	9441	9542	All patients who received IL-2 suffered from IL-2-related toxicity grade 1 (24%), 2 (67%), or 3 (9%).
preoperative administration of interleukin-2 (IL-2)	immunomonitoring without immunomodulation	Tumour-specific survival after 5 years	1639	1768	Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04).
